MARKET

ZYME

ZYME

Zymeworks
NASDAQ
24.23
+0.63
+2.67%
After Hours: 24.23 0 0.00% 16:10 03/25 EDT
OPEN
23.96
PREV CLOSE
23.60
HIGH
24.82
LOW
23.96
VOLUME
522.63K
TURNOVER
--
52 WEEK HIGH
28.49
52 WEEK LOW
9.03
MARKET CAP
1.79B
P/E (TTM)
-22.5207
1D
5D
1M
3M
1Y
5Y
1D
Zymeworks to Highlight Pipeline and Asset Strategy at Key Investor Conferences
TipRanks · 1d ago
Zymeworks to Present at Needham Virtual Healthcare Conference and Bloom Burton Healthcare Investor Conference
Reuters · 1d ago
Zymeworks Announces Participation in Upcoming Investor Conferences
Barchart · 2d ago
Weekly Report: what happened at ZYME last week (0316-0320)?
Weekly Report · 2d ago
Does Zymeworks (ZYME) Pan-RAS ADC Push Reveal a Durable Edge in Targeted Oncology?
Simply Wall St · 03/19 05:09
Zymeworks Highlights New Ziihera Data to Broaden HER2 Cancer Reach
TipRanks · 03/18 12:23
Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting
TipRanks · 03/18 11:51
Zymeworks Announces Jazz Pharmaceuticals To Present Four Abstracts Featuring Data From Clinical Studies Evaluating Ziihera At American Association for Cancer Research Annual Meeting
Benzinga · 03/18 11:47
More
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.